EU/3/12/1094:

Modified recombinant human C-type natriuretic peptide (Vosoritide)

Overview

On 24 January 2013, orphan designation (EU/3/12/1094) was granted by the European Commission to BioMarin Europe Ltd, United Kingdom, for modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia.

The sponsorship was transferred to BioMarin International Limited, Ireland, in February 2019.

This medicine is now known as Vosoritide.

Key facts

Active substance
Modified recombinant human C-type natriuretic peptide (Vosoritide)
Intented use
Treatment of achondroplasia
Date of designation
24/01/2013
Orphan designation status
Positive
EU designation number
EU/3/12/1094

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

BioMarin International Limited
Shanbally
Ringaskiddy
County Cork P43 R298
Ireland
Tel. +353 1479430
E-mail: shanbally@bmrn.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

Related content

How useful was this page?

Add your rating